COX-2 as an early diagnostic marker of virus-associated human malignant neoplasms

Voprosy Virusologii

Volumn 57, Issue 2, 2012, Pages 4-8

  Diduk, S V ^a   Smirnova, K V ^a   Gurtsevich, V E ^a  

^a N N BLOKHIN RUSSIAN CANCER RESEARCH CENTER   (Russian Federation)

Author keywords

Carcinogenesis; Cyclooxygenase 2; Epstein Barr virus; Hepatitis B virus; Human papillomavirus; LMP1 protein; Oncomarker; Vaccination

Indexed keywords

CYCLOOXYGENASE 2; TUMOR MARKER;

EARLY DIAGNOSIS; ENZYMOLOGY; EPSTEIN BARR VIRUS; HEPATITIS B VIRUS; HUMAN; METABOLISM; PAPILLOMA VIRUS; REVIEW; VIROLOGY; VIRUS INFECTION;

CYCLOOXYGENASE 2; EARLY DIAGNOSIS; HEPATITIS B VIRUS; HERPESVIRUS 4, HUMAN; HUMANS; PAPILLOMAVIRIDAE; TUMOR MARKERS, BIOLOGICAL; TUMOR VIRUS INFECTIONS;

EID: 84864959646     PISSN: 05074088     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (32)

1. Castle P. E., Rodriguez A. C., Burk R. D. et al. Short term persistence of human papillomavirus and risk of cervical precancer and cancer: population based cohort study // Br. Med. J.- 2009. - Vol. 339.-P. 1-13.
2. Chang M. H. Hepatitis B virus and cancer prevention // Recent Results Cancer Res.-2011.-Vol. 188. - P. 75-84.
3. Chia W. K., Wang W. W., Teo M. et al. A phase II study evaluating the safety and efficacy of an adenovirus- {Delta} LMP1-LMP2 transduced dendritic cell vaccine in patients with advanced metastatic nasopharyngeal carcinoma // Ann. Oncol. - 2011. - Aug. 4.- Epub ahead of print
4. Cullen J. M., Brown D. L, Kissling G. E. et al. Aflatoxin and/ or hepatitis B virus induced tumor spectrum in a genetically engineered hepatitis B virus expression and Trp53 haploinsufficient mouse model system for hepatocarcinogenesis // Toxicol. Pathol.- 2009. - Vol. 37. - P. 333-342.
5. Dunne E. F, Unger E. R., Sternberg M. et al. Prevalence of HPV infection among females in the United States // J. A. M. A. - 2007. -Vol. 297-P.813-819.
6. Fendri A., Khabir A., Hadhri-Guiga B. et al. Overexpression of COX-2 and LMP1 are correlated with lymph node in Tunisian NPC patients//Oral Oncol. - 2008.-Vol. 44.-P. 710-715.
7. Greenhough A., Smartt H. J., Moore A. E. et al. The COX-2/PGE2 pathway: key roles in the hallmarks of cancer and adaptation to the tumour microenvironment // Carcinogenesis. - 2009. - Vol. 30. - P. 377-386.
8. Harris R. E. Cycloxygcnasc-2 (cox-2) and the inflammogcnesis of cancer//Subcell. Biochem. -2007. - Voi. 42. -P. 93-126.
9. Jingting J, Changping W, Ning X. et al. Clinical evaluation of serum alpha-fetoprotein-lgM immune complexes on the diagnosis of primamry hepatocellular carcinoma // J. Clin. Lab. Anal. - 2009. -Vol. 23.-P.213-218.
10. Kim S. H., Oh J. M., No J. H. et al. Involvement of NF-kappaB and AP-1 in COX-2 uprcgulation by human papillomavirus 16 E5 oncoprotein // Carcinogenesis. - 2009. - Vol. 30. - P. 753-757.
11. Koga H., Sakisaka S., Ohishi M. et al. Expression of cycloxygenase-2 in human hepatocellular carcinoma: relevance to tumor dedifferentiation // Hepatology. - 1999. - Vol. 29. - P. 688-696.
12. Kose S., Turken M, Cavdar G. et al. Evaluation of vaccination results in high-risk paitents included in hepatitis B vaccination program //Hum. Vaccin. -2010. - Vol. 6. - P. 903-905.
13. Lai L. C., Cheong S. K., Goh K. L. et al. Clinical usefulness of tumour markers // Malaysia J. Pathol. - 2003. - Vol. 25. - P. 83-105.
14. Lara-Pezzi E., Gomez-Caviro M. K, Calvez B. G. et al. The hepatitis B virus X protein promotes tumor cell invasion by inducing membrane-type matrix metalloproteinase-1 and cyclooxygenase-2 expression // J. Clin. Invest. - 2002. - Vol. 110. - P. 1831-1838.
15. Liaw Y. F, Brunetto M. R., Hadziyannis S. The natural history of chronic HBV infection and geographical differences // Antiviral Ther.-2010.-Vol. 15.-P.25-33.
16. Mainou B. A., Raab-Traub N. J. LMP1 strain variants: biological and molecular properties // J. Virol. - 2006. - Vol. 80. - P. 6458-6468.
17. McCormack P L., Joura E. A. Quadrivalent human papillomavirus (types 6, 11, 16, 18) recombinant vaccine (Gardasil): a review of its use in the prevention of premalignant genital lesions, genital cancer and genital warts in women // Drugs. - 2010. - Vol. 70. - P. 2449-2474.
18. McKeage K., Romanowski B. AS04-adjuvanted human papillomavirus (HPV) types 16 and 18 vaccine (Cervarix): a review of its use in the prevention of premalignant cervical lesions and cervical cancer causally related to certain oncogenic HPV types // Drugs. - 2011. - Vol. 71. - P. 465-488.
19. Mitchell A., Newton J, M., Brite K. et al. Cyclooxygenase 2 expression in cervical intraepithelial neoplasia and vulvar cancer // J. Low Genit. Tract Dis. - 2007. - Vol. 11. - P. 80-85.
20. Mohan S., Epstein J. B. Carcinogenesis and cyclooxygenase: the potential role of COX-2 inhibition in upper aerodigestive tract cancer // Oral Oncol. - 2003. - Vol. 39. - P. 537-546.
21. Murano S., Inoue H., Tanabe T. et al. Induction of cyclooxygenase-2 by Epstein-Barr virus latent membrane protein 1 is involved in vascular endothelial growth factor production in nasopharyngeal carcinoma cells // Proc. Natl. Acad. Sci. USA. - 2001. - Vol. 98. -P.6905-6910.
22. Piriou E., Kimmel R., Chelimo K. et al. Serological evidence for long-term Epstein-Barr virus reactivation in children living in a holoendemic malaria region of Kenya // J. Med. Virol. 2009. - Vol. 81.-P. 1088-1093.
23. Qin N., Zhang S. P., Reitz T. L. et al. Cloning, expression, and functional characterization of human cyclooxygenase-1 splicing variants: evidence for intron 1 retention // J. Pharmacol. Exp. Ther. -2005.-Vol. 315.-P. 1298-1305.
24. Saldivar J. S., Lopez D., Feldman R. A. et al. COX-2 overexpression as a biomarker of early cervical carcinogenesis: a pilot study // Gynecol. Oncol.-2007.-Vol. 107. - P. 155-162.
25. Sharma-Walia N., George P. A., Patel K. et al. NFAT and CREB regulate Kaposi's sarcoma-associated herpesvirus-induced cyclooxygenase 2 (COX-2) // J. Virol. - 2010. - Vol. 84. - P. 12733-12753.
26. Sharma-Walia N., Raghu H., Sadagopan S. et al. Cyclooxygenase 2 induced by Kaposi's sarcoma-associated herpesvirus early during in vitro infection of target cells plays a role in the maintenance of latent viral gene expression // J. Virol. -2006. - Vol. 80. - P.6534-6552.
27. Soo R., Putti T, Tao Q. et al. Overexpression of cyclooxygenase-2 in nasopharyngeal carcinoma and association with epidermal growth factor receptor expression // Arch. Otolaryngol. - 2005. -Vol. 131,-P. 147-152.
28. Subbaramaiah K., Dannenberg A. J. Cyclooxygcnasc-2 transcription is regulated by human papillomavirus 16 E6 and E7 oncoproteins: evidence of a corepressor/coactivator exchange // Cancer Res. - 2007. - Vol. 67. - P. 3976-3985.
29. Trottier H., Franco E. L. The epidemiology of genital human papillomavirus infection // Vaccine. - 2006. - Vol. 24. - P. S1-S15.
30. Venters C., Graham W, Cassidy W Recombivax-HB: perspectives past, present and future // Expert Rev. Vaccines. - 2004. - Vol. 3. -P.119-129.
31. Villegas E., Santiago O., Sorlozano A., Gutierrez J. New strategies and patent therapeutics in EBV-associated diseases // Mini Rev. Med. Chem. - 2010. - Vol. 10. - P. 914-927.
32. Young L. S., Rickinson A. B. Epstein-Barr virus: 40 years on//Nat. Rev. Cancer. - 2004. - Vol. 4. - P. 757-768.